Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass compounding” of GLP-1 obesity treatments and “deceptive marketing.”
The Medicare Advantage industry has aggressively sued the federal government to overturn reduced quality ratings and keep billions of taxpayer-funded bonuses.
Ending the federal LGBTQ+ suicide prevention line is a public health failure, write two leaders in prevention and crisis response.
Philanthropy can provide enormous benefits, and should be encouraged, but it can also create terrible reputational damage when a donor turns out to be toxic,…
A lot stands in the way of bipartisan health care policymaking, threatening PBM reform and extenders.
The use of the antibiotic doxycycline to reduce STIs appears to be fueling some antibiotic resistance, according to new research.
The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment continues.
A coalition of academic organizations has finalized a proposed alternative to the Trump administration’s plan to cut billions of dollars in research
Ending the federal LGBTQ+ suicide prevention line is a public health failure, write two leaders in prevention and crisis response.
HHS will limit immigrants’ access to more federally funded programs, like health clinics and head start.
Future doctors from underserved communities will have a harder time paying for med school under the new federal loan caps, one student writes.
